Skip to content
Screener

Theravance Biopharma TBPH Gross margin

Discontinued — last reported Q4 '17

Gross margin at other companies

Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
94.3%-1.7pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
93.4%+3.7pp
LQD
Liquidia CorporationLQDA
58.1%-18.7pp
United Therapeutics logo
United TherapeuticsUTHR
86.1%-2.8pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
95.5%+23.5pp
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
90.4%+0.8pp

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$876.93M+56.9%
Enterprise value$629.34M+94.5%
P/E7.7×-35.3×
P/S8×+0.7×

Profitability

See full
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

gross profit/total revenue=60.8%

Based on trailing twelve months.

The source filing: Theravance Biopharma’s 10-K, filed February 27, 2020. Open the filing →

Filed
Feb 27, 2020, 4:40 PM EST
Fiscal year
FY2019
Accession
0001558370-20-001644

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.